Use of sodium‐glucose co‐transporter‐2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations

Author:

Khoo Chin Meng1,Deerochanawong Chaicharn2ORCID,Chan Siew Pheng3,Matawaran Bien4,Sheu Wayne Huey‐Herng5ORCID,Chan Juliana6ORCID,Mithal Ambrish7,Luk Andrea6ORCID,Suastika Ketut8,Yoon Kun‐Ho9ORCID,Ji Linong10ORCID,Man Nguyen Huu11,Pollock Carol12

Affiliation:

1. National University of Singapore Singapore Singapore

2. Rajavithi Hospital, College of Medicine Rangsit University Bangkok Thailand

3. Department of Medicine University of Malaya Medical Center Kuala Lumpur Malaysia

4. Department of Medicine, Section of Endocrinology, Diabetes and Metabolism University of Santo Tomas Hospital Manila Philippines

5. Division of Endocrinology and Metabolism, Department of Internal Medicine Taichung Veterans General Hospital Taichung Taiwan

6. Department of Medicine and Therapeutics Hong Kong Institute of Diabetes and Obesity and Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong

7. The Medicity Gurgaon India

8. Faculty of Medicine Udayana University, Sanglah General Hospital Bali Indonesia

9. Department of Endocrinology & Metabolism, Seoul St Maryʼs Hospital The Catholic University of Korea Seoul South Korea

10. Peking University Peopleʼs Hospital Peking China

11. FV Hospital Ho Chi Minh City Vietnam

12. The University of Sydney School of Medicine Sydney New South Wales Australia

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3